Pembrolizumab

Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma

Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma

By

Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.

Pembrolizumab Improves Long-term Survival in Advanced Melanoma

Pembrolizumab Improves Long-term Survival in Advanced Melanoma

By

Four in 10 patients with newly diagnosed and previously treated advanced melanoma were alive 3 years after initiating pembrolizumab.

Immunotherapy Drugs Shows Early Promise in Treating Tumors of Rare, Virus-linked Skin Cancer

By

Half of 25 patients with Merkel cell carcinoma treated with pembrolizumab experienced significant tumor shrinkage that lasted almost 3 times longer than conventional chemotherapy, and some had no remaining disease after treatment.

Pembrolizumab Achieves Response and Increased Survival in Melanoma

Pembrolizumab Achieves Response and Increased Survival in Melanoma

By

Overall objective responses occurred in one-third of patients with melanoma who were treated with pembrolizumab in a phase 1b clinical trial.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs